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Abstract
Background: Combined idiopathic pulmonary fibrosis (IPF) with pulmonary emphysema (CPFE) is a syndrome with
a characteristic presentation of upper lobe emphysema and lower lobe fibrosis. While CPFE is a strong determinant
of secondary precapillary pulmonary hypertension (PH), there is limited evidence regarding the management of
patients with CPFE and PH.
Case presentation: A 63 year-old male presented in 2006 with dyspnoea on exertion having quit smoking in
2003. Clinical examination, together with high resolution computed tomography, bronchoalveolar lavage, and
echocardiographic assessments, suggested a diagnosis of CPFE without PH. In 2007, the patient received
intravenous cyclophosphamide, N-acetylcysteine, and short-term anticoagulation treatment. Due to remission of
acute exacerbations, the patient received triple combination therapy (prednisone, N-acetylcysteine and
azathioprine). Upon progressive clinical worsening, long-term supplemental oxygen therapy was initiated in 2009.
Repeated right heart catheterisation in 2011 confirmed PH and worsening pulmonary haemodynamics, and off-
label ambrisentan therapy was initiated. Dyspnoea remained at follow-up, although significant haemodynamic
improvement was observed.
Conclusion: CFPE is a distinct but under-recognized and common syndrome with a characteristic presentation.
Further studies are needed to ascertain the etiology, morbidity, and mortality of CPEF with or without PH, and to
evaluate novel management options.
Introduction
There is an increasing awareness of comorbid conditions
frequently associated with idiopathic pulmonary fibrosis
(IPF), including emphysema, cardiovascular disease,
thromboembolic disease, and obstructive sleep apnoea.
Recent retrospective data suggest that 21 to 33% of
patients with IPF may have co-existing emphysema [1-3].
The association of emphysema with IPF has been termed
the combined pulmonary fibrosis and emphysema (CPFE)
syndrome [4,5] to account for the characteristic clinical,
functional, imaging, and outcome features. Characteristics
of patients with CPFE syndrome include male predomi-
nance, tobacco smoking, severe dyspnoea, subnormal
spirometry findings, severely impaired transfer capacity for
carbon monoxide [4,6,7], hypoxemia upon exercise, high
frequency of paraseptal emphysema, and a high probability
(30–50%) of severe pulmonary hypertension (PH) impact-
ing upon an already poor prognosis [2,4]. However, very
limited evidence is available regarding the management of
patients with PH in the CPFE syndrome.
Clinical case
Observation
A 63 year-old man presented in 2006 with dyspnoea on
exertion (New York Heart Association (NYHA) func-
tional class II). He had smoked 20 pack-years and quit
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smoking in 2003, had no professional exposure, and had
a history of hypercholesterolemia treated with atorvasta-
tin, and surgery for prostatic adenocarcinoma followed
by complete remission. Clinical examination demon-
strated fine ’Velcro‘-like crackles of the lung bases, with
no finger clubbing, and the absence of clinical signs of
connective tissue disease. The patient’s body mass index
was 25 kg/m².
Diagnostic tests
IPF was suspected, however lung volumes were subnor-
mal, with forced vital capacity (FVC) of 91% of predicted,
total lung capacity (TLC) of 79%, and a residual volume of
64%. Forced expiratory volume in one second (FEV1) was
85% of predicted; the FEV1/FVC was 71%. Transfer capa-
city for carbon monoxide (DLco) was 72% and transfer
coefficient was 81%. Partial arterial pressure of oxygen was
11.7 kPa, decreasing to 8.2 kPa with exercise. High resolu-
tion computed tomography (HRCT) of the chest demon-
strated predominantly paraseptal emphysema of the upper
zones of the lungs, and interstitial lung disease of the basal
regions, with intralobular reticulation and ground glass
opacities (Figure 1). Bronchoalveolar lavage (BAL) differ-
ential cell counts showed 10% neutrophils, 1% eosinophils,
2% lymphocytes, and 87% macrophages. Echocardiography
did not demonstrate PH. The patient was diagnosed with
CPFE syndrome.
Treatment and patient management
In 2007, the patient presented with acute exacerbation
of pulmonary fibrosis fulfilling international criteria [8],
and BAL culture was negative; pulmonary embolism and
left heart disease were excluded. The patient received
intravenous cyclophosphamide (6-monthly pulses), N-
acetylcysteine, and short-term anticoagulation treatment,
but experienced clinical and HRCT remission of the
acute exacerbation. He was further treated with triple
combination therapy (prednisone, N-acetylcysteine 1.8 g
per day, and azathioprine), with progressive clinical wor-
sening despite therapy.
In 2009, dyspnoea was NYHA functional class III. FVC
was 67% of predicted, TLC was 52%, residual volume
33%, FEV1 66%, FEV1/FVC 75%, DLco 21% and Kco 50%.
Long-term supplemental oxygen therapy was initiated,
and PaO2 under 2 L/min supplemental oxygen was 11.2
kPa. The 6-min walk distance was 240 m, with peripheral
oxygen saturation of 76% while breathing 4 L/min sup-
plemental oxygen. The patient presented with episodes of
syncope at exertion. Echocardiography demonstrated
dilated right heart cavities, with estimated systolic pul-
monary arterial pressure of 45 mmHg. Right heart cathe-
terisation confirmed precapillary PH (Table 1).
In 2011, repeated catheterisation showed worsening of
pulmonary haemodynamics, and off-label ambrisentan
therapy (5 mg per day) was initiated, with no change in
oxygen saturation and PaO2. At follow-up evaluation,
dyspnoea was unchanged; however significant haemody-
namic improvement was observed (Table 1), and 6-min
walk distance improved by 27 m.
Discussion
This patient case highlights a number of characteristics
of the CPFE syndrome that contribute to distinctly differ-
ent management compared with IPF alone (i.e. in the
absence of emphysema). CPFE is a syndrome with charac-
teristic presentation, including very low diffusion capacity
contrasting with subnormal spirometry, occurring in
heavy smokers with severe dyspnoea and exercise limita-
tion. It may be overlooked due to subnormal lung
volumes, however gas exchanges are severely altered.
Despite moderate or severe emphysema, a large propor-
tion of patients with CPFE have FEV1/FVC >70% indicat-
ing that GOLD criteria for chronic obstructive lung
disease may not be applicable [3]. In addition, diagnostic
criteria of IPF may not apply, owing to difficulties in
ascertaining honeycomb changes in patients with asso-
ciated emphysema UIP [9] and a high frequency of mild-
to-moderate ground glass opacities [4].
A limited amount of data is available regarding lung
pathology in patients with CPFE. Indeed, severe alteration
of gas exchange and emphysema features at imaging may
explain why lung biopsy is rarely performed, as in this pre-
sented case. A variety of pathology patterns of pulmonary
fibrosis have been reported in patients with CPFE, includ-
ing predominantly UIP pattern [10], however nonspecific
interstitial pneumonia [11], desquamative interstitial pneu-
monia (with extensive fibrosis), respiratory bronchiolitis,
associated interstitial lung disease, airspace enlargement
with fibrosis, or unclassifiable smoking-related interstitial
fibrosis, may be observed.
This case further indicates that the natural course of dis-
ease in CPFE may encompass episodes of acute exacerba-
tion of pulmonary fibrosis, a complication seldom reported
previously in CPFE. Further, the presence of significant
emphysema impacts FVC measurement, and thus changes
in FVC alone may not be a reliable indicator of disease
[7,12]. Patients with CPFE should be excluded from IPF
clinical trials [5]. In fact, a decline in FEV1 by 10% or more
at 6 or 12 months may be useful in assessing disease pro-
gression [3], which contrasts with the monitoring of IPF
alone using serial changes in FVC and DLco. The main pre-
dictor of subsequent mortality is precapillary pulmonary
hypertension [2,4], which portends a dismal prognosis [13].
Whether survival of patients with IPF is impacted by coex-
istent emphysema (e.g. CPFE) is controversial, due to diffi-
culties in controlling for disease severity [2,14]. A
composite physiologic index may account for the extent of
disease [15].
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Figure 1 High resolution computed tomography (HRCT) of the chest demonstrating predominantly paraseptal emphysema of the upper areas
of the lungs, and interstitial lung disease of the basal regions, with intralobular reticulation and ground glass opacities.
Table 1 Right heart catheterisation in the patient with combined pulmonary fibrosis and emphysema.
Date May 2009 Feb 2011 June 2011
PAP m (mmHg) 26 38 25
PCWP (mmHg) 8 12 9
SvO2 (%) 68 59 -
Cardiac index (L/min/m²) 2.25 3.39 3.02
PVR (dyn/s/cm5) 356 488 246
RAP (mmHg) 8 7 5
Vasoreactivity Negative - -
Treatment None Initiation of ambrisentan ambrisentan
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There are currently no specific recommendations for the
treatment of pulmonary fibrosis, emphysema or PH in
the setting of CPFE. It is unknown whether treating these
components of disease influences clinical outcomes.
Patients with CPFE are likely to require long-term oxygen
therapy. The presented case indicates that therapy specific
for pulmonary hypertension may improve haemody-
namics, as in other isolated reports [13,16], but the poten-
tial clinical and survival benefit is unknown. Results of a
recent trial (‘ARTEMIS-IPF’, NCT00768300) have showed
that ambrisentan therapy is not beneficial and may even
be deleterious in patients with IPF, regardless of associated
PH, and should now be avoided in this condition. Treat-
ment specific for PH may in some cases impair oxygena-
tion by worsening ventilation/perfusion mismatch. Recent
data have recommended against combination therapy with
prednisone, azathioprine, and high-dose N-acetylcysteine
in IPF management [17]. Monotherapy using N-acetylcys-
teine is currently widely used in this setting, yet without
evidence.
In conclusion, CPFE is a syndrome with characteristic
presentation, and with a prognosis dominated by preca-
pillary PH-associated with a poor prognosis, despite
moderate haemodynamic severity. Further study is
required regarding therapies targeting pulmonary fibro-
sis or PH.
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